UNSPSC 51392202: Apraclonidine or iopidine

This classification denotes an alpha-adrenergic agonist with the molecular formula C9H10Cl2N4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 843CEN85DI, chemically known as 2,6-dichloro-n-(4,5-dihydro-1h-imidazol-2-yl)benzene-1,4-diamine but generally known as apraclonidine, which bears US NIH Compound Identifier 2216. Apraclonidine most often comes in base and hydrochloride forms. European Medicines Agency schedules Apraclonidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05539MIG.

UNSPSC 51392202 Apraclonidine or iopidine is a Commodity code that in recent state and local procurement activity covers pharmaceutical products and related health systems — though the code's nominal scope (a specific ophthalmic agent) does not align cleanly with the opportunities currently being solicited under it. State and local health agencies, county health departments, and state health and human services commissions are the primary issuing bodies posting under this code. The work being solicited ranges from direct procurement of naloxone and drug deactivation systems for community health initiatives to exploratory requests for information about direct-to-manufacturer pharmaceutical contracting models and pharmacy benefit program restructuring. These are expansive health procurement activities that diverge from the specific pharmaceutical compound the code nominally describes.

Recent activity is concentrated in Florida and Texas. Seminole County, Florida posted IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida; the bid deadline was July 26, 2023. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription fulfillment capabilities and cost management strategies for a proposed Therapeutic Pharmacy Initiative, with response due April 3, 2026. Both opportunities signal state and local appetite for pharmaceutical supply optimization and alternative contracting models, though the code itself shows limited recent activity and substantial scope mismatch with its nominal definition.